Home Alzheimer’s Disease FDA Grants Fast Track Designation for Balstilimab to Treat Advanced Cervical Cancer

FDA Grants Fast Track Designation for Balstilimab to Treat Advanced Cervical Cancer

The FDA granted Agenus fast track designation to investigate balstilimab monotherapy as well as balstilimab and zalifrelimab as a combination therapy for the treatment of advanced cervical cancer, according to a recent Agenus press release.1

Agenus, an immune-oncology organization with a number of agents that activate immune responses to cancers, also expects to file 2 biologic licensing applications this year for the balstilimab and zalifrelimab combination, as well as balstilimab monotherapy as treatment for metastatic cervical cancer.

“We are pleased to have now been granted Fast Track designation by FDA for both balstilimab as a monotherapy and in combination with zalifrelimab (anti-CTLA-4) in recognition of the high unmet medical need in second line cervical cancer,” Dr. Anna Wijatyk, head of clinical development at Agenus, said in a press release. “The Fast Track designation…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments